Please ensure Javascript is enabled for purposes of website accessibility

Alkermes' Bad News Could Be Good News for Johnson & Johnson

By Todd Campbell – Apr 4, 2018 at 9:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A stumble at Alkermes could mean one less competitor for a new drug making its way through J&J's pipeline.

Alkermes' (ALKS -1.09%) hopes for a speedy review of its depression drug ALKS-5461 were dashed earlier this week when the Food and Drug Administration (FDA) issued it a Refusal to File letter, citing inadequate proof of efficacy. Alkermes won't find out exactly what the FDA wants to see from it until it has a meeting with the regulator, but it appears that a new trial may be necessary. The delay caused by the FDA's concerns could be considerable, and if so, it could be good news for Johnson & Johnson (JNJ -1.00%), which is developing a competing drug: esketamine.

Filling a gap in care

Major depression is nothing to take lightly. Unlike those "blue" type feelings we all get from time to time, patients with major depression disorder (MDD) endure periods of overwhelming sadness that can significantly impair their quality of life.

Close-up of doctor's and patient's hands resting on table between them

Image source: Getty Images.

According to the National Institutes of Mental Health (NIMH), about 16 million adults in the U.S. have at least one episode of major depression every year. The World Health Organization (WHO) estimates that 350 million people suffer depression globally.

Since so many people suffer from major depression, treating depression is a multibillion-dollar market. Yet, despite the widespread use of antidepressants, there's still an unmet need for the 30% of patients who fail to respond to existing treatment choices.

A new approach hits a roadblock

ALKS-5461 works differently than traditional antidepressants. In an intriguing approach, it combines the opiate receptor blocker, buprenorphine, with samidorphan, a drug that reduces the euphoria associated with buprenorphine and thus, its risk of abuse.

In January, Alkermes filed for FDA approval of ALKS-5461 after the drug delivered positive efficacy in its Forward-5 study. In that trial, it significantly improved ratings from baseline on a common depression measure versus a placebo in patients who were resistant to antidepressants. 

The positive trial results, however, followed two phase 3 trial failures and apparently, the victory in just one of these three late-stage studies wasn't enough to convince the FDA of ALKS-5461's value.

On Monday, the FDA issued Alkermes a Refusal to File letter, and while management won't have a full understanding of the FDA's objection until it has its meeting, it did report that the FDA's position is that the application package doesn't provide enough insight for it to conduct a "substantive review" because of "insufficient evidence of overall effectiveness for the proposed indication." Alkermes also said that "additional well-controlled clinical trials are needed prior to the resubmission."

The FDA also wants more information relating to the bioavailability of buprenorphine in patients taking ALKS-5461.

The door opens wider for J&J

The worst-case scenario of the FDA requiring Alkermes to conduct an additional trial could be best-case scenario for Johnson & Johnson's esketamine. Like ALKS-5461, esketamine targets treatment-resistant patients by using a unique mechanism of action.

Sold under the brand names Ketanest and Ketanest S for use as a general anesthetic, esketamine's midstage trials as an antidepressant are encouraging. In treatment-resistant patients, esketamine nasal spray delivered statistically meaningful improvements on a common depression scale when compared to a placebo. Esketamine is currently in phase 3 trials that are expected to read out data beginning in Q2 2018, and if the data is good, J&J plans to file for FDA approval in adults at imminent risk for suicide by the end of this year.

What to watch for next

Esketamine's data will begin being released soon, so investors should keep tabs on Johnson & Johnson's press releases over the coming weeks. Depression trials are notorious for failure due to the placebo effect, so it wouldn't be too surprising if at least one of esketamine's studies misses the mark. As long as the majority of its trials succeed, J&J's likely to follow through on filing for approval. As for Alkermes, the company should be able to tell investors more about ALKS-5461's future once it sits down with the FDA. Overall, however, it appears that another trial could be necessary, and that suggests investors might want to focus on other drugs in Alkermes' pipeline.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Alkermes and Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
$22.68 (-1.09%) $0.25
Johnson & Johnson Stock Quote
Johnson & Johnson
$164.69 (-1.00%) $-1.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.